Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials

Clinical Trials

OncoMed completes patient enrollment in phase 2 trial of tarextumab in SCLC OncoMed Pharmaceuticals has completed patient enrollment in the Phase 2 "PINNACLE" clinical trial of tarextumab (anti-Notch2/3, OMP-59R5) for the treatment of small cell lung cancer (SCLC).
Contract Research & Services > Clinical Trials > News
Rigel's fostamatinib meets main goal in phase 3 study in chronic ITP By PBR Staff Writer
A phase 3 study assessing Rigel Pharmaceuticals’ fostamatinib to treat chronic/persistent immune thrombocytopenia (ITP) met its primary endpoint.
Contract Research & Services > Clinical Trials > News Amgen unveils positive results from phase 3 study of Prolia in patients receiving glucocorticoid therapy Amgen announced positive top-line results from the primary analysis conducted in a Phase 3 randomized, double-blind, double-dummy, active-controlled study evaluating the safety and efficacy of Prolia (denosumab) compared with risedronate in patients receiving glucocorticoid treatment.
Contract Research & Services > Clinical Trials > News
See more Clinical Trials news

Latest Clinical Trials News and Insight

View all Clinical Trials news or find news targeted to your interests
CTI BioPharma reports mixed results for pacritinib in advanced myelofibrosis
By PBR Staff Writer
CTI BioPharma announced that a phase 3 clinical trial of pacritinib for high-risk patients with advanced myelofibrosis met one of the co-primary endpoints.
Contract Research & Services > Clinical Trials > News
BirchBioMed completes anti-scarring drug clinical trial
BirchBioMed announced that a unique and ground-breaking topical treatment developed by University of British Columbia (UBC) researchers to prevent scarring has completed a Health Canada approved Phase I trial.
Contract Research & Services > Clinical Trials > News
NeuroDerm starts phase III trial of NDO612L in Parkinson's disease
By PBR Staff Writer
Clinical stage pharmaceutical firm NeuroDerm has started a phase III clinical trial, evaluating NDO612L for the treatment of Parkinson's disease (PD).
Contract Research & Services > Clinical Trials > News
Highland Therapeutics' subsidiary starts phase 2 Trial for HLD100 in pediatric ADHD patients
Highland Therapeutics' subsidiary, Ironshore Pharmaceuticals & Development, has initiated enrollment in a Phase 2 study of HLD100, which is currently under development as a new amphetamine-based treatment option for patients with Attention Deficit/Hyperactivity Disorder (ADHD).
Contract Research & Services > Clinical Trials > News
Insys reports phase 3 trial of Sublingual Buprenorphine spray meets primary endpoint
Insys Therapeutics reported that the Phase 3 trial for the Buprenorphine Sublingual Spray met its primary endpoint.
Contract Research & Services > Clinical Trials > News
Novartis’ BAF312 meets main goal in secondary progressive multiple sclerosis trial
By PBR Staff Writer
A phase III study, assessing the efficacy and safety of Novartis’ BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS), met its primary endpoint of a reduction in the risk of disability progression, versus placebo.
Contract Research & Services > Clinical Trials > News
Watch Vaisala's video on What's new in Environmental Monitoring
The Vaisala viewLinc monitoring system: Your controlled environments can be complex. You need a monitoring system to safeguard huge investments, a fail-safe system that monitors a wide range of parameters.
Contract Research & Services > Clinical Trials > Videos
4D pharma starts dosing in phase 1 trial with Thetanix to treat Paediatric Crohn's disease
4D pharma has started dosing in a phase 1 clinical trial with Thetanix for the treatment of Paediatric Crohn's disease ('PCD').
Contract Research & Services > Clinical Trials > News
Auris Medical's ear tinnitus drug Keyzilen fails to meet co-primary endpoints in phase 3 trial
Auris Medical announced top-line results from the Phase 3 TACTT2 trial with KeyzilenTM (AM-101) in acute inner ear tinnitus.
Contract Research & Services > Clinical Trials > News
Indivior’s opioid-treatment study of RBP-6000 meets primary and secondary endpoints
By PBR Staff Writer
A phase 3 clinical trial of Indivior’s RBP-6000 buprenorphine monthly depot, a new drug for the treatment of opioid use disorder, has met both primary and secondary endpoints versus placebo.
Contract Research & Services > Clinical Trials > News
View all Clinical Trials news or find news targeted to your interests